Table 2 Fertility outcomes and ovarian tissue usage according to chemotherapy induced gonadotoxicity risk (n = 77)
Parameter | Risk for chemotherapy induced gonadotoxicitya | ||
|---|---|---|---|
Low risk | Moderate risk | High risk | |
N | 18 | 22 | 37 |
Age at treatment | 20.1 + 4.2 (19) | 22.5 + 5.7 (22) | 26.1 + 6.5 (24) |
Chemotherapy prior to OTCP | 4/18 (22.2%) | 4/22 (18.2%) | 13/38 (34.2%) |
GnRHa during treatment | 0/18 (0%) | 2/22 (9.1%) | 6/37 (16.2%) |
Follow-up time (years) | 9.0 + 6.2 (8) | 9.8 + 4.5 (10) | 9.6 + 5.6 (8) |
Menopause symptomsb | 3/18 (16.7%) | 6/22(27.3%) | 19/37(51.4%) |
Menstrual irregularity | 4/18 (22.2%) | 7/22 (31.8%) | 19/37 (51.4%) |
Amenorrhea | 3/18 (16.7%) | 4/22 (18.2%) | 9/37 (24.3%) |
Attempt to conceive | 8/18 (44.4%) | 12/22 (54.6%) | 25/37 (67.6%) |
Spontaneous pregnancyb | 7/8 (87.5%) | 7/12 (58.3%) | 8/25 (32.0%) |
IVF treatment (n of patients) | 0 | 5 | 15 |
IVF pregnancy | N/A | 2/5 (40.0%) | 4/15 (26.7%) |
Tissue usage indexc | N/A | 16.7% (2/12) | 20.0% (5/25) |
Ovarian tissue auto-transplantation pregnancy | N/A | 1/2 (50.0%) | 3/5 (60.0%) |
Oocyte donation pregnancy | N/A | 2/5 (40.0%) | 2/15 (13.3%) |